NEW YORK (AP) – Mylan Inc. said that its partner Pfizer Inc. will market the EpiPen allergic reaction syringe in Japan.
The companies did not disclose financial terms of their agreement, which gives Pfizer exclusive rights to market EpiPen in Japan.
EpiPen is a pre-filled syringe used to treat severe allergic reactions. Pfizer, New York, owns the product and Mylan, based in Canonsburg, Pa., markets it in the U.S.
Japanese regulators have already approved EpiPen.
Date: August 7, 2012
Source: Associated Press
Filed Under: Drug Discovery